Cindy Boer

248 | Chapter 5.2 References 1. Centers for Disease Control and Prevention (CDC). Prevalence of doctor-diagnosed arthritis and ar- thritis-attributable activity limitation–United States, 2010–2012. Mmwr. Morb. Mortal. Wkly. Rep. 62, 869–873 (2013). 2. Centers for Disease Control and Prevention (CDC). Prevalence and most common causes of dis- ability among adults–United States, 2005. Mmwr. Morb. Mortal. Wkly. Rep. 58, 421–426 (2009). 3. Ayral, X., Pickering, E. H., Woodworth, T. G., Mackillop, N. & Dougados, M. Synovitis: a potential predictive factor of structural progression of medial tibiofemoral knee osteoarthritis–results of a 1 year longitudinal arthroscopic study in 422 patients. Osteoarthr. Cartil. 13, 361–367 (2005). 4. Kraus, V. B. et al. Direct in vivo evidence of activated macrophages in human osteoarthritis. Osteo- arthr. Cartil. 24, 1613–1621 (2016). 5. Dahaghin, S., Bierma-Zeinstra, S. M. A., Koes, B. W., Hazes, J. M. W. & Pols, H. A. P. Do metabolic factors add to the effect of overweight on hand osteoarthritis? The Rotterdam Study. Ann. Rheum. Dis. 66, 916–920 (2007). 6. Saberi Hosnijeh, F. et al. Association between biomarkers of tissue inflammation and progression of osteoarthritis: evidence from the Rotterdam study cohort. Arthritis Res. Ther. 18, 81 (2016). 7. Utomo, L., Bastiaansen-Jenniskens, Y. M., Verhaar, J. A. N. & van Osch, G. J. V. M. Cartilage inflam- mation and degeneration is enhanced by pro-inflammatory (M1) macrophages in vitro, but not in- hibited directly by anti-inflammatory (M2) macrophages. Osteoarthr. Cartil. 24, 2162–2170 (2016). 8. Reyes, C. et al. Association between overweight and obesity and risk of clinically diagnosed knee, hip, and hand osteoarthritis: a population-based cohort study. Arthritis Rheumatol. 68, 1869–1875 (2016). 9. Berenbaum, F., Griffin, T. M. & Liu-Bryan, R. Review: metabolic regulation of inflammation in oste- oarthritis. Arthritis Rheumatol. 69, 9–21 (2017). 10. Winer, D. A., Luck, H., Tsai, S. & Winer, S. The intestinal immune system in obesity and insulin re- sistance. Cell Metab. 23, 413–426 (2016). 11. Cani, P. D. et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57, 1470–1481 (2008). 12. Cani, P. D. et al. Changes in gut microbiota control inflammation in obese mice through a mecha- nism involving GLP-2-driven improvement of gut permeability. Gut 58, 1091–1103 (2009). 13. Turnbaugh, P. J. et al. A core gut microbiome in obese and lean twins. Nature 457, 480–484 (2009). 14. Brun, P. et al. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am. J. Physiol. Liver Physiol. 292, G518–G525 (2007). 15. Luck, H. et al. Regulation of obesity-related insulin resistance with gut anti-inflammatory agents. Cell Metab. 21, 527–542 (2015). 16. Kaparakis-Liaskos, M. & Ferrero, R. L. Immune modulation by bacterial outer membrane vesicles. Nat. Rev. Immunol. 15, 375–387 (2015). 17. Bonnington, K. E. & Kuehn, M. J. Protein selection and export via outer membrane vesicles. Bio- chim. Biophys. Acta 1843, 1612–1619 (2014). 18. Brown, L., Wolf, J. M., Prados-Rosales, R. & Casadevall, A. Through the wall: extracellular vesicles in Gram-positive bacteria, mycobacteria and fungi. Nat. Rev. Microbiol. 13, 620–630 (2015). 19. Bomberger, J. M. et al. Long-distance delivery of bacterial virulence factors by Pseudomonas aeruginosa outer membrane vesicles. PLoS Pathog. 5, e1000382 (2009). 20. Levy, M., Blacher, E. & Elinav, E. Microbiome, metabolites and host immunity. Curr. Opin. Microbiol. 35, 8–15 (2017). 21. Ohto, U., Fukase, K., Miyake, K. & Shimizu, T. Structural basis of species-specific endotoxin sensing by innate immune receptor TLR4/MD-2. Proc. Natl Acad. Sci. USA 109, 7421–7426 (2012). 22. Huang, Z. Y., Stabler, T., Pei, F. X. & Kraus, V. B. Both systemic and local lipopolysaccharide (LPS) burden are associated with knee OA severity and inflammation. Osteoarthr. Cartil. 24, 1769–1775